Although most NSCLC patients with EGFR mutations benefit from treatment with 1st or 2nd EGFR-TKIs, the clinical efficacy differs among individuals, and resistance eventually develops within 9–14 months. This evidence concerns the gene EGFR and non-small cell lung carcinoma.